Vera Therapeutics VERA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $114.35M-67.8% | $354.73M+514% | $57.77M+17.6% | $49.12M-10.8% | $55.09M-40.5% | ||
| $482.41M+34.1% | $359.86M-18.1% | $439.62M-13.4% | $507.71M-5.1% | $534.74M-2.5% | ||
| $615.8M-15.5% | $728.88M+42.6% | $511.31M-10.5% | $571.35M-5.7% | $606.08M-6.9% | ||
| $621.74M-15.4% | $734.73M+42.0% | $517.5M-10.5% | $578.53M-5.2% | $610.17M-6.9% | ||
| $66.91M+7.5% | $62.27M+29.6% | $48.03M+38.5% | $34.69M+32.4% | $26.19M+18.3% | ||
| $45.15M-15.5% | $53.46M+27.6% | $41.88M+24.8% | $33.55M+53.3% | $21.89M-13.7% | ||
| $75.03M+0.3% | $74.84M+0.3% | $74.65M+0.2% | $74.46M+46.3% | $50.91M+0.4% | ||
| $122.04M-6.3% | $130.21M+9.8% | $118.62M+7.6% | $110.25M+46.7% | $75.17M-4.3% | ||
| $72K+1.4% | $71K+10.9% | $64K0.0% | $64K0.0% | $64K0.0% | ||
| -$881.9M-15.9% | -$760.87M-13.6% | -$669.77M-13.6% | -$589.48M-14.9% | -$512.94M-11.2% | ||
| $499.7M-17.3% | $604.52M+51.6% | $398.88M-14.8% | $468.28M-12.5% | $535M-7.3% | ||
| $621.74M-15.4% | $734.73M+42.0% | $517.5M-10.5% | $578.53M-5.2% | $610.17M-6.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Vera Therapeutics cover its short-term obligations?
- Its current ratio is 13.64 — current assets exceed current liabilities.
- Where does Vera Therapeutics's balance sheet data come from?
- Every line is extracted from Vera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.